Biological Activity
Tapinarof (Benvitimod, GSK2894512) is an AHR-modulating compound for skin inflammation and keratinocyte research. Tapinarof improved skin lesions and reduced cytokines in the IL-23/IL-17/IL-22 axis.
In Vitro
No separate compound-specific cell or biochemical result is available from the sources summarized here.
In Vivo
| Endpoint | Model / conditions / source | Reported result |
|---|---|---|
| Imiquimod model | Mouse psoriasis-like dermatitis induced by topical imiquimod. [1] | Tapinarof improved skin lesions and reduced cytokines in the IL-23/IL-17/IL-22 axis. |
| Keratinocyte phenotype | Imiquimod model skin. [1] | Reduced keratinocyte proliferation and abnormal differentiation accompanied the anti-inflammatory response. |
| Contrasting IL-23 model | Separate IL-23-injection mouse model. [1] | Tapinarof worsened disease, with greater epidermal thickness and dysplastic differentiation. |
Compound and Evidence Context
| Endpoint | Model / conditions / source | Reported result |
|---|---|---|
| Model dependence | AHR-ligand pharmacology across two psoriasis models. [1] | The opposite responses are material to product selection; efficacy from one model should not be generalized to another. |
Interpretation
The direction of the response depends on the experimental model; the study does not support uniformly anti-inflammatory effects.
